Pacific Biosciences of California, Inc.

PACB

CIK 0001299130 · Quarterly mode · latest period FY2025 (Q4) (ending 2025-12-31) · sourced from SEC EDGAR

At a glance · FY2025 (Q4)

Revenue
$45M
↑+13.8% +$5Mvs FY2024 (Q4)
Gross Profit
$17M
↑+64.7% +$7Mvs FY2024 (Q4)

Quality Score

Quality score

6-dimension fundamental snapshot · latest annual filed values · S&P 500 calibration

Weak
31/100
  • Profitability
    0ROIC -170.9% (10% = solid, 20%+ = moat)
  • Liquidity
    100Current Ratio 5.15 (above 1.5 = solid)
  • Leverage
    20D/E 1.59 (under 0.5 = conservative)
  • Efficiency
    0Asset Turnover 0.16x (1.0+ = capital-efficient)
  • Growth
    63Revenue YoY +13.8% (10% = solid, 25%+ = elite)
  • Margin Trend
    0Op Margin -101.1% · trend -170.1pts (4Q avg vs prior 4Q)

Calibrated to S&P 500 medians. Each sub-score is computed from a single CFA-grade ratio (Profitability = ROIC, Liquidity = Current Ratio, Leverage = D/E, Efficiency = Asset Turnover, Growth = Revenue YoY, Margin Trend = 4Q operating-margin avg vs prior 4Q). Overall = simple mean.

Capital allocation · trailing 4 quarters

how the company spent its cash
Capex (TTM)
$3M
investment in PP&E
Stock-based comp (TTM)
$42M
non-cash dilution

Balance sheet · 2025-12-31

latest filed snapshot
Total assets
$784M
everything owned
Total liabilities
$779M
everything owed
Stockholders' equity
$5M
shareholder claim
Net debt
$833M
LT debt minus cash

Recent performance · 63 quarters

Revenue↑+13.8% +$5M
$45M
Net Income↑+37.4% +$23M
$-38M
Free Cash Flow↑+46.8% +$756K
$-861K
Operating Margin↑+59.2pts
-101.1%

Drill down